Filing Scope and Business Context
The provided filing is Health Sciences Acquisitions Corporation’s unaudited Form 10-Q for the quarter ended June 30, 2019, filed August 12, 2019. It does not appear to be an Immunovant, Inc. filing or a 2019 Q1 filing. Health Sciences Acquisitions Corporation was a blank-check company formed to identify and complete a business combination, with an intended focus on healthcare, biopharma and medical technology businesses in North America or Europe. No operating business had commenced as of June 30, 2019.
Financial Highlights
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 |
|---|---|---|
| Operating revenue | None | None |
| Operating costs and franchise taxes | $92,342 | $92,792 |
| Interest income | $341,558 | $341,558 |
| Net income | $182,749 | $182,299 |
| Net cash used in operating activities | Not separately provided | $230,733 |
- Net income was generated entirely by interest income on funds held in the Trust Account, rather than operating revenue.
- As of June 30, 2019, cash outside the Trust Account was $1.9 million, while cash and marketable securities held in the Trust Account totaled $115.3 million, including $115.3 million of U.S. Treasury bills and $8,783 of cash.
- Total assets were $117.4 million. Liabilities were $4.1 million, including a $4.025 million deferred underwriting fee payable.
- Common stock subject to possible redemption was recorded as temporary equity at $108.3 million.
- The company had no long-term debt, capital leases, operating leases or off-balance-sheet financing arrangements. Related-party promissory note and advances were repaid in May 2019.
- The company paid a $10,000 monthly fee to its sponsor for office space, utilities and administrative support, beginning May 9, 2019.
Material Changes Versus the Prior Comparable Period
- The company completed its initial public offering on May 14, 2019, selling 11.5 million units at $10.00 per unit for gross proceeds of $115.0 million.
- It simultaneously sold 10.0 million private warrants to its sponsor for $5.0 million.
- $115.0 million was placed in the Trust Account. At December 31, 2018, no Trust Account existed and cash was $325,000.
- Total assets increased from $405,000 at December 31, 2018 to $117.4 million at June 30, 2019, primarily due to the IPO and Trust Account funding.
- Cash increased to $1.9 million from $325,000, while the related-party promissory note declined from $300,000 to zero.
- The company changed from a pre-IPO formation-stage entity to a publicly traded special purpose acquisition company seeking a target business.
Outlook, Risks and Unusual Items
- Management expected no operating revenue until after completion of an initial business combination and anticipated continuing legal, accounting, public-company and due-diligence expenses.
- The company had until May 14, 2021 to complete a business combination. If unsuccessful, it must cease operations, redeem 100% of public shares using the Trust Account, and liquidate, subject to applicable law and creditor obligations.
- Public stockholders may redeem shares for a pro rata portion of the Trust Account in connection with a business combination. Warrants would receive no liquidation distribution and could expire worthless if no transaction is completed.
- The initial business combination generally must involve a target or targets with a fair market value of at least 80% of the Trust Account assets, excluding deferred underwriting fees and taxes, and must leave the company with at least $5,000,001 of net tangible assets.
- The sponsor committed to purchase $20.0 million of company shares in a private placement concurrent with a business combination.
- The deferred $4.025 million underwriting fee would become payable only if a business combination is completed.
- Management stated that additional financing might be required if transaction costs, redemptions or acquisition funding needs exceed available resources. A successful transaction could also involve substantial dilution or additional debt.
- No material changes to the IPO prospectus risk factors were reported, and no legal proceedings or subsequent events requiring disclosure were identified.
- Disclosure controls and procedures were evaluated as effective, with no material changes to internal control over financial reporting.
Investor Verification Points
- Verify the issuer and reporting period: the supplied document identifies Health Sciences Acquisitions Corporation and the quarter ended June 30, 2019, not Immunovant, Inc. or 2019 Q1.
- Confirm the status, terms and permitted use of the $115.3 million Trust Account, including redemption protections and the $4.025 million deferred underwriting fee.
- Review the timetable and conditions for completing a business combination by May 14, 2021, including the liquidation consequences if no transaction closes.
- Assess sponsor conflicts, founder share terms, private warrants, related-party support arrangements and the proposed $20.0 million sponsor share purchase.
- Confirm that reported net income reflects Trust Account interest rather than recurring operating profitability, and that no operating revenue had been generated.
- Review potential dilution from public and private warrants, founder shares, redemption activity and any equity or debt financing used in a future transaction.